At month @ , suvorexant ( @ patients in the efficacy population ) showed greater efficacy than placebo ( @ in the efficacy population ) in improving sTST ( @ min vs @ min ; difference @ , @ % CI @ to @ ; p < @ ) and sTSO ( -@ min vs -@ min , difference -@ , -@ to -@ ; p = @ ) .